ArticleDrug delivery and translational research2014
Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.
Article in Drug delivery and translational research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Understanding the Impact of Particle Size and Crystal Habit of Mesalamine Drug Substances on Their Packing, Wetting, and Dissolution Behaviour: A Science-based Approach for Selection of API Vendor.AAPS PharmSciTech · 2026Article
- Understanding the Influence of Molarity, Buffer Capacity, and pH on Product-specific Guidance Dissolution Method for Developing a Discriminatory Dissolution Method for the Development of Mesalamine Products.AAPS PharmSciTech · 2026Article
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Process Optimisation, Pharmaceutical Characterisation, and in vitro Activity of Mesalamine Nanocrystals in PMA-differentiated THP-1 cell Lines in the Late Inflammatory and Profibrotic Phase.AAPS PharmSciTech · 2026Article
- From bench to bowel: translating targeted drug delivery through gastrointestinal barriers.Frontiers in bioengineering and biotechnology · 2026Review
- Development of a pH Gradient Dissolution Condition to Predict the Behavior of Delayed Release Formulations under Fed In Vivo Condition.AAPS PharmSciTech · 2025Article
- Influence of Milling Parameters on Crystal Morphology, Thermal Behavior, and Dissolution of Mesalamine Nanocrystals.Pharmaceutical research · 2025Article
- Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery.International journal of molecular sciences · 2025Review
- Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease.Pharmaceutics · 2022Review
- Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.AAPS PharmSciTech · 2021Review
- Colon targeted bioadhesive pellets of curcumin and cyclosporine for improved management of inflammatory bowel disease.Drug delivery and translational research · 2020Article
- Stimuli-Responsive Polymeric Nanosystem for Colon Specific Drug Delivery.Advanced pharmaceutical bulletin · 2020Review
- Significance of Ligand-Anchored Polymers for Drug Targeting in the Treatment of Colonic Disorders.Frontiers in pharmacology · 2019Review
- Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease.Acta biomaterialia · 2018Article
- Colon-targeted oral drug delivery systems: design trends and approaches.AAPS PharmSciTech · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colon targeted dosage forms have been extensively studied for the localized treatment of inflammatory bowel disease. These dosage forms not only improve the therapeutic efficacy but also reduce the incidence of adverse drug reactions and hence improve the patient compliance. However, complex and highly variable gastro intestinal physiology limits the clinical success of these dosage forms. Biopharmaceutical characteristics of these dosage forms play a key role in rapid formulation development and ensure the clinical success. The complexity in product development and clinical success of colon targeted dosage forms are based on the biopharmaceutical characteristics such as physicochemical properties of drug substances, pharmaceutical characteristics of dosage form, physiological conditions and pharmacokinetic properties of drug substances as well as drug products. Various in vitro and in vivo techniques have been employed in past to characterize the biopharmaceutical properties of colon targeted dosage forms. This review focuses on the factors influencing the biopharmaceutical performances of the dosage forms, in vitro characterization techniques and in vivo studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.